ASH

Ashland (ASH) reported earnings 30 days ago. What's next for the stock?

Ashland launches Permexa sodium caprate to support oral peptide and biologic development with enhanced processing and permeability.

WILMINGTON, Del., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH), is announcing the launch of permexa™ sodium caprate, a high-performance intestinal permeation enhancer designed to support the scalable development and commercialization of oral peptide, biologic and low-permeability drug products, including rapidly expanding GLP-1 agonists and related therapeutic pipelines.

Ashland Inc. (ASH) remains a Buy, with the investment case now centered on activist-driven M&A potential and strategic alternatives. Life Sciences and Personal Care segments, comprising 82% of gross EBITDA, continue to deliver growth and margin stability, underpinning valuation. Multiple activist investors, including Standard Industries and Ancora, have driven board changes, capital allocation reviews, and engagement with potential acquirers.

WILMINGTON, Del., Aug. 07, 2026 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE: ASH) has declared a quarterly cash dividend of $0.42 cents per share on the company's common stock.

Ashland Inc. (ASH) Q3 2026 Earnings Call Transcript

Ashland NYSE: ASH reported higher sales across all four business units in its fiscal third quarter of 2026, supported by volume growth, pricing actions and demand in its Life Sciences and Personal Care operations. The company reaffirmed its full-year sales and adjusted EBITDA outlook, while lowering its adjusted earnings-per-share growth forecast because of a higher tax rate tied to unfavorable discrete items.

ASH's Q3 sales beat estimates as volume growth lifted all segments, but adjusted earnings missed and the company lowered its fiscal 2026 EPS growth outlook.

Ashland (ASH) came out with quarterly earnings of $1.02 per share, missing the Zacks Consensus Estimate of $1.03 per share. This compares to earnings of $1.04 per share a year ago.

Sales of $497 million, up seven percent from the prior-year quarter Income from continuing operations of $41 million, or $0.89 per diluted share Adjusted Income from Continuing Operations Excluding Intangibles Amortization Expense of $47 million, or $1.02 per diluted share Net income of $16 million, or $0.35 per diluted share Sales volumes rose six percent from the prior-year quarter, with gains achieved across all business units Adjusted EBITDA of $109 million, down four percent from the prior-year quarter, primarily reflecting growth in Life Sciences and Personal Care, more than offset by lower Specialty Additives and Intermediates earnings  Cash flows provided by operating activities of $121 million; Ongoing Free Cash Flow2 of $103 million Reaffirming full‑year fiscal 2026 sales guidance of $1,835-$1,870 million and Adjusted EBITDA guidance of $385-$400 million WILMINGTON, Del., July 28, 2026 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced financial results1 for the third quarter of fiscal year 2026, which ended June 30, 2026, and reaffirmed its full-year fiscal 2026 sales and Adjusted EBITDA outlook.